Ignite Creation Date:
2024-05-06 @ 12:00 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01469039
Status:
COMPLETED
Last Update Posted:
2019-01-30
First Post:
2011-11-08
Brief Title:
A Study to Evaluate the Efficacy and Safety of ALKS 9072 Also Known as Aripiprazole Lauroxil ALKS 9070 or ARISTADA in Subjects With Schizophrenia
Sponsor:
Alkermes Inc
Organization:
Alkermes Inc
Study Overview
Official Title:
A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will determine the efficacy of ALKS 9072 also known as aripiprazole lauroxil or ALKS 9070 for the treatment of schizophrenia in subjects experiencing an acute exacerbation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None